XENE
Xenon Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$59.69
−1.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 7.5M | — | — | 9.4M |
| Cost of Revenue | 77.7M | 2.5M | 2.6M | 167.5M | — |
| Gross Profit | (77.7M) | 5.0M | (2.6M) | (167.5M) | 9.4M |
| Operating Expenses | |||||
| R&D Expense | 352.5M | 300.9M | 210.4M | 167.5M | 105.8M |
| SG&A Expense | 89.1M | 79.6M | 68.9M | 46.5M | 32.8M |
| General & Admin Expense | 89.1M | 79.6M | 68.9M | 46.5M | 32.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (77.7M) | (2.5M) | (2.6M) | (167.5M) | — |
| Total Operating Expenses | 363.9M | 378.0M | 276.7M | 46.5M | 138.6M |
| Cost and Expenses | 441.6M | 380.6M | 279.3M | 214.1M | 138.6M |
| Operating Income (EBIT) | (441.6M) | (373.1M) | (279.3M) | (214.1M) | (129.1M) |
| Non-Operating | |||||
| Interest Income | 31.5M | 26.8M | 41.9M | 27.6M | 8.7M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 31.5M | 26.8M | 41.9M | 27.6M | 8.7M |
| Other Non-Op Income/Expense | 30.4M | 28.2M | 40.9M | 31.4M | 3.9M |
| Non-Operating Income (excl Interest) | (23.0M) | (28.2M) | (40.9M) | — | — |
| EBT (Pre-Tax Income) | (411.1M) | (344.9M) | (238.4M) | (182.7M) | (125.3M) |
| Income Tax Expense | (1.9M) | 1.0M | (4.1M) | (292.0K) | 118.0K |
| Bottom Line | |||||
| Net Income | (409.2M) | (345.9M) | (234.3M) | (182.4M) | (125.4M) |
| Earnings from Cont. Ops | (409.2M) | (345.9M) | (234.3M) | (182.4M) | (125.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (409.2M) | (345.9M) | (234.3M) | (182.4M) | (124.9M) |
| Per Share | |||||
| Basic EPS | ($4.74) | ($4.36) | ($3.01) | ($2.73) | ($2.06) |
| Diluted EPS | ($4.74) | ($4.36) | ($3.01) | ($2.73) | ($2.06) |
| Revenue Per Share | $0.00 | $0.09 | $0.00 | $0.00 | $0.16 |
| Shares | |||||
| Basic Shares Outstanding | 99.6M | 79.3M | 77.9M | 66.9M | 60.5M |
| Diluted Shares Outstanding | 99.6M | 79.3M | 77.9M | 66.9M | 60.5M |
| Profitability Metrics | |||||
| EBITDA | (416.8M) | (342.4M) | (235.9M) | (210.5M) | (127.7M) |
| D&A | 1.8M | 2.5M | 2.6M | 3.5M | 1.4M |
| EBIT | (418.6M) | (344.9M) | (238.4M) | (214.1M) | (129.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026